contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Exactly, and today is March 20, 2026? However, the Q1 results were released at the same time as always.

Revenio – Publication dates of notices to the General Meeting     Year Publication date Source     2025 19.3.2025 stock exchange release   2024 14.3.2024 stock exchange release   2023 16.3.2023 stock exchange release   2022 17.3.2022 stock exchange release   2021 18.3.2021 stock exchange release

Varelius leaving the sinking ship and Toijala to be the next CEO for Qt..?

I find it noteworthy that Revenio has not yet issued a notice of the annual general meeting. Perhaps this is due to M&A matters. At least in the past couple of years, the notice of the annual general meeting had already been issued by this time.

Apparently, CEO Toijala has enough time to focus outside of Revenio, as he is a candidate for QT’s board of directors. In my opinion, in smaller companies, resources are so limited that there would be plenty to invest in one’s own company, be it customer relationships, new market areas, new product applications, product features, R&D, AI, mergers and acquisitions, etc., etc. Well, maybe something from QT will benefit Revenio as well? NOTICE OF QT GROUP OYJ’S ANNUAL GENERAL MEETING KUTSU QT GROUP OYJ:N VARSINAISEEN YHTIÖKOKOUKSEEN | Kauppalehti

I have been a Revenio shareholder for a very long time, but nowadays its weight in my portfolio is quite small – and that is not exactly a coincidence. The case seems to be stalling. There is growth, but not the kind that this story should be producing. Clearly, more was expected from the HOME family, and AI has not yet become a concrete earnings driver, even though heavy investments are being made into it. The valuation is starting to be quite moderate, which makes this a bit of a “middle-of-the-roader”: the downside doesn’t look large, but a clear driver for better performance is missing. Acquisitions could be one way to accelerate growth, but I don’t see them as strictly necessary – and the method of execution matters a lot. Deals done with the company’s own balance sheet would be clearly more attractive than paying with shares at the current valuation, although the latter has its own sides (e.g., slight dilution of ownership). The bull case still rests on the current products scaling better and AI starting to actually show in the numbers. For now, however, this is more about expectation than evidence. There is also a small option that the same sales force could sell more, but there isn’t really evidence of this yet. My feeling at the moment:  A good company, but the story needs concrete results. The valuation is starting to look interesting, but it’s not yet a sufficient reason to increase the weight.

Juha and I recorded a video about Revenio today. Juha defends Revenio’s Buy recommendation against my doubts.                    Inderes              Onko Revenio arvoansa? - Inderes    Aika: 18.03.2026 klo 16.20 Revenion osake on kosahtanut 75 % huipuistaan. Onko Reveniolla takana vain loistava menneisyys?

Revenio Group

Under the iCare brand, Revenio offers world-class tonometers, fundus imaging devices and perimeters. In recent years, the company has added software solutions to its offering, moving from being an equipment provider to a holistic eye diagnostics solution provider. 

<p>Under the iCare brand, Revenio offers world-class tonometers, fundus imaging devices and perimeters. In recent years, the company has added software solutions to its offering, moving from being an equipment provider to a holistic eye diagnostics solution provider. The core business is growing very profitably, the market has sound growth drivers, and the company’s products have strong competitive advantages. At the same time, the company is creating future growth by developing new growth initiatives, of which Revenio has an excellent track record. </p> 

	2022	23e	24e
Revenue	97.0	111.4	129.6
growth-%	23.1 %	14.9 %	16.3 %
EBIT (adj.)	30.9	34.0	39.5
EBIT-% (adj.)	31.8 %	30.5 %	30.5 %
EPS (adj.)	0.86	0.98	1.15
Dividend	0.36	0.42	0.55
Dividend %	0.9 %	2.3 %	3.0 %
P/E (adj.)	44.6	18.5	15.8
EV/EBITDA	30.6	12.5	10.4

Revenio: Holistic value creation on the horizon

Login required

Key Estimate Figures18.03.2023

Forum discussions